Hoag to Participate in Groundbreaking Study Aiming to Help Prevent Memory Loss Due to Alzheimer s Disease
News provided by
Share this article
Share this article
NEWPORT BEACH, Calif., June 3, 2021 /PRNewswire/ Hoag s Pickup Family Neurosciences Institute has started recruiting volunteers for a study testing an investigational treatment that aims to help prevent the earliest stages of memory loss due to Alzheimer s disease.
Funded by the National Institutes of Health (NIH) and Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo), the AHEAD Study is the first Alzheimer s disease research study to recruit people as young as 55 years old who are at risk of developing symptoms of Alzheimer s disease as they get older. It introduces a personalized approach that will tailor treatment dosing levels to a participant s particular risk of memory loss related to Alzheimer s disease.
The key barometers hovered near the flat line in early afternoon trade. Metal shares tumbled while autos and FMCG shares bucked weak market trend.
At 12:20 IST, the barometer index, the S&P BSE Sensex, rose 6.05 points or 0.01% at 51,943.49. The Nifty 50 index lost 15.25 points or 0.10% at 15,567.55. The Nifty pared losses after hitting the day s low of 15,528.30 in early afternoon trade.
In the broader market, the S&P BSE Mid-Cap index fell 0.39% while the S&P BSE Small-Cap index slipped 0.51%.
The market breadth was weak. On the BSE, 1,112 shares rose and 1,857 shares fell. A total of 124 shares were unchanged.
Derivatives:
The NSE s India VIX, a gauge of market s expectation of volatility over the near term, jumped 5.92% to 17.89. The Nifty 29 July 2021 futures were trading at 15,564.45, at a discount of 3.10 points as compared with the spot at 15,567.55.
Glenmark Pharmaceuticals (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel1 Tablets, 200 mg and 400 mg of Eisai, Inc.
Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on 16 May 2016.
According to IQVIATM sales data for the 12 month period ending April 2021, the Banzel Tablets, 200 mg and 400 mg market achieved annual sales of approximately $285.3 million.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
The newly launched drug is a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc. Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems.
Read more about Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg on Business Standard. The medicines are a therapeutic equivalent of Banzel®